Mr. Hayim Raclaw reports

ALZAI HEALTH CORP. JOINS ALZHEIMER'S ASSOCIATION BUSINESS CONSORTIUM TO ADVANCE ALZHEIMER'S RESEARCH AND INNOVATION

Alzai Health Corp. has joined the Alzheimer's Association Business Consortium (AABC), an initiative of the Alzheimer's Association focused on advancing Alzheimer's disease and dementia research through innovation, collaboration, and knowledge sharing.

The AABC brings together companies across biotechnology, diagnostics, medical devices, and clinical research to encourage collaboration and innovation within the Alzheimer's research ecosystem.

Alzai's membership represents an important step in expanding its engagement within the Alzheimer's research community. The company's proprietary artificial-intelligence-driven platform utilizes routine health care data, including standard laboratory results and demographic information, to identify individuals who may be at elevated risk for Alzheimer's disease before clinical diagnosis. The technology is designed to support earlier risk stratification, clinical trial recruitment and more informed decision-making among health care providers, pharmaceutical companies, clinical research organizations and health care payers.

Through its participation in the AABC, Alzai intends to exchange knowledge, engage with fellow members, and explore potential research and commercial collaborations aligned with its long-term development and commercialization strategy.

"Joining the Alzheimer's Association Business Consortium is an important milestone for Alzai as we continue to advance our technology and strengthen our presence within the Alzheimer's research community," said Hayim Raclaw, chief executive officer of Alzai Health. "We believe AI-driven risk stratification using routine healthcare data has the potential to support earlier patient identification and more efficient clinical research. We look forward to engaging with fellow AABC members and exploring opportunities to contribute to the advancement of Alzheimer's research."

About Alzai Health Corp.

Alzai Health is a health care technology company developing non-invasive, artificial intelligence-driven disease risk identification solutions using routine health care data. The company's proprietary platform is designed to identify individuals who may be at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. Alzai's technology has been validated on large-scale health care data sets and is designed for integration into existing health care infrastructure, including electronic medical record systems, cloud-based environments and enterprise health care platforms.

We seek Safe Harbor.